Document is current
Any future updates will be listed below
-
Authors
Lasocki, Sigismond http://orcid.org/0000-0003-2901-4628
Asfar, Pierre
Jaber, Samir
Ferrandiere, Martine
Kerforne, Thomas
Asehnoune, Karim
Montravers, Philippe
Seguin, Philippe
Peoc’h, Katell
Gergaud, Soizic
Nagot, Nicolas
Lefebvre, Thibaud
Lehmann, Sylvain
,
Lasocki, Sigismond
Asfar, Pierre
Jaber, Samir
Ferrandiere, Martine
Kerforne, Thomas
Asehnoune, Karim
Montravers, Philippe
Seguin, Philippe
Peoc’h, Katell
Gergaud, Soizic
Nagot, Nicolas
Lefebvre, Thibaud
Lehmann, Sylvain
Beloncle, François
Mercat, Alain
Gaillard, Thomas
Leger, Maxime
Rineau, Emmanuel
Sargentini, Cyril
Geneve, Claire
Puy, Herve
Mercier, Grégoire
Marin, Gregory
Delaby, Constance
Hirtz, Christophe
Chanques, Gerald
Roquilly, Antoine
Boisson, Matthieu
Dahyot-Fizelier, Claire
Mimoz, Olivier
Isslame, Sonia
Launey, Yoann
Barbaz, Mathilde
-
Funding
Funding for this research was provided by:
ministère de la santé (STIC 2012 N° 2-12-0006)
- License Information
-
More Information
Article History
Received: 6 September 2020
Accepted: 7 December 2020
First Online: 15 February 2021
Ethics approval and consent
: Following French law [], the study protocol has been approved by an IRB (Comité de Protection des Personnes (CPP) Sud Méditerranée IV, REF 13 07 05, protocol No 2013-A00964-41) and by the CNIL (Commission Nationale de l’Informatique et des Libertés, MR-001 of May 7, 2012 (No 1585321 v0)). The protocol has been registered by the competent authority (ANSM—Agence Nationale de Sécurité du Médicament et des produits de santé) under the reference number 2013-192 and on under the reference NCT02276690 (October 28, 2014). A signed informed consent was obtained from each patient (or from his/her next of kin if the patient was unable to consent).
: Not applicable.
: Sigismond Lasocki has received speaker honoraria from VIFOR Pharma, MASIMO, LFB and fee as member of advisory board and/or steering committee from VIFOR Pharma and Pfizer.. SLa is the coordinator of a multicenter randomized controlled trial on iron and tranexamic acid in hip fractured patients (HIFIT study, NCT02972294), for which PHARMACOSMOS gives iron for free. Philippe Seguin has received fee from LFB. None of the other authors have a competing interest to declare.
